GPOH Guidelines for Diagnosis and First-line Treatment of Patients with Neuroblastic Tumors, update 2025
Thorsten Simon, Theresa Thole, S Castelli, Beate Timmermann, Danny Jazmati, Rudolf Schwarz, Jörg Fuchs, Steven W. Warmann, Jochen Hubertus, Matthias Schmidt, Julian M.M. Rogasch, Friederike Körber, Christian Vokuhl, Jürgen Schäfer, Johannes H. Schulte, Hedwig E. Deubzer, Carolina Rosswog, Matthias Fischer, Peter Lang, Thorsten Langer, Kathy Astrahantseff, Holger N. Lode, Barbara Hero, Angelika Eggert
Abstract
The clinical course of neuroblastoma is more heterogeneous than any other malignant disease. Many low-risk patients experience regression after limited or even no chemotherapy. However, more than half of high-risk patients die from disease despite intensive multimodal treatment. Precise disease characterization for each patient at diagnosis is key for risk-adapted treatment. The guidelines presented here incorporate results from national and international clinical trials to produce recommendations for diagnosing and treating neuroblastoma patients in German hospitals outside of clinical trials.